Literature DB >> 32952126

A structural view of PA2G4 isoforms with opposing functions in cancer.

Brendan W Stevenson1, Michael A Gorman2, Jessica Koach3,4, Belamy B Cheung4,5, Glenn M Marshall5,6, Michael W Parker1,2, Jessica K Holien7,8,9.   

Abstract

The role of proliferation-associated protein 2G4 (PA2G4), alternatively known as ErbB3-binding protein 1 (EBP1), in cancer has become apparent over the past 20 years. PA2G4 expression levels are correlated with prognosis in a range of human cancers, including neuroblastoma, cervical, brain, breast, prostate, pancreatic, hepatocellular, and other tumors. There are two PA2G4 isoforms, PA2G4-p42 and PA2G4-p48, and although both isoforms of PA2G4 regulate cellular growth and differentiation, these isoforms often have opposing roles depending on the context. Therefore, PA2G4 can function either as a contextual tumor suppressor or as an oncogene, depending on the tissue being studied. However, it is unclear how distinct structural features of the two PA2G4 isoforms translate into different functional outcomes. In this review, we examine published structures to identify important structural and functional components of PA2G4 and consider how they may explain its crucial role in the malignant phenotype. We will highlight the lysine-rich regions, protein-protein interaction sites, and post-translational modifications of the two PA2G4 isoforms and relate these to the functional cellular role of PA2G4. These data will enable a better understanding of the function and structure relationship of the two PA2G4 isoforms and highlight the care that will need to be undertaken for those who wish to conduct isoform-specific structure-based drug design campaigns.
© 2020 Stevenson et al.

Entities:  

Keywords:  ErbB3-binding protein 1 (EBP1); cancer; cancer biology; drug target; proliferation-associated protein 2G4 (PA2G4); protein targeting; receptor structure-function; structure-function

Year:  2020        PMID: 32952126      PMCID: PMC7681029          DOI: 10.1074/jbc.REV120.014293

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  73 in total

1.  Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication.

Authors:  P Nash; X Tang; S Orlicky; Q Chen; F B Gertler; M D Mendenhall; F Sicheri; T Pawson; M Tyers
Journal:  Nature       Date:  2001-11-29       Impact factor: 49.962

Review 2.  For IRES trans-acting factors, it is all about location.

Authors:  S M Lewis; M Holcik
Journal:  Oncogene       Date:  2007-09-03       Impact factor: 9.867

3.  F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex.

Authors:  D Skowyra; K L Craig; M Tyers; S J Elledge; J W Harper
Journal:  Cell       Date:  1997-10-17       Impact factor: 41.582

4.  The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.

Authors:  Yuexing Zhang; Xin-Wei Wang; Danijela Jelovac; Takeo Nakanishi; Myoung-Hee Yu; Damilola Akinmade; Olga Goloubeva; Douglas D Ross; Angela Brodie; Anne W Hamburger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-30       Impact factor: 11.205

5.  Significance of Ebp1 and p53 protein expression in cervical cancer.

Authors:  L Liu; X D Li; H Y Chen; J S Cui; D Y Xu
Journal:  Genet Mol Res       Date:  2015-10-02

6.  Sequence and structure comparison suggest that methionine aminopeptidase, prolidase, aminopeptidase P, and creatinase share a common fold.

Authors:  J F Bazan; L H Weaver; S L Roderick; R Huber; B W Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

7.  Distinct Interactions of EBP1 Isoforms with FBXW7 Elicits Different Functions in Cancer.

Authors:  Yuli Wang; Pengju Zhang; Yunshan Wang; Panpan Zhan; Chunyan Liu; Jian-Hua Mao; Guangwei Wei
Journal:  Cancer Res       Date:  2017-02-16       Impact factor: 12.701

8.  Expression, purification, crystallization and preliminary crystallographic analysis of the proliferation-associated protein Ebp1.

Authors:  Eva Kowalinski; Gert Bange; Klemens Wild; Irmgard Sinning
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-08-25

9.  Heregulin regulates the ability of the ErbB3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription.

Authors:  Yuexing Zhang; Anne W Hamburger
Journal:  J Biol Chem       Date:  2004-04-08       Impact factor: 5.157

10.  Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin.

Authors:  J Y Yoo; X W Wang; A K Rishi; T Lessor; X M Xia; T A Gustafson; A W Hamburger
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  5 in total

1.  ERBB3 methylation and immune infiltration in tumor microenvironment of cervical cancer.

Authors:  Xiaoyue Yang; Ying Chen; Mei Li; Weipei Zhu
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

2.  PA2G4 promotes the metastasis of hepatocellular carcinoma by stabilizing FYN mRNA in a YTHDF2-dependent manner.

Authors:  Sheng Sun; Yiyang Liu; Meiling Zhou; Jinyuan Wen; Lin Xue; Shenqi Han; Junnan Liang; Yufei Wang; Yi Wei; Jinjin Yu; Xin Long; Xiaoping Chen; Huifang Liang; Zhao Huang; Bixiang Zhang
Journal:  Cell Biosci       Date:  2022-05-07       Impact factor: 7.133

3.  ERBB3 binding protein 1 promotes the progression of malignant melanoma through activation of the Wnt/ β-catenin signaling pathway.

Authors:  Yanqiu Bao; Jingshu Cui; Yuyang Yue; Shuxia Cao; Xiangdan Li; Lan Liu
Journal:  Cancer Cell Int       Date:  2022-01-29       Impact factor: 5.722

4.  Structural Characteristics of the 5'-Terminal Region of Mouse p53 mRNA and Identification of Proteins That Bind to This mRNA Region.

Authors:  Joanna Szpotkowska; Kamil Szpotkowski; Jerzy Ciesiołka
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

5.  α-Trifluoromethyl Chalcones as Potent Anticancer Agents for Androgen Receptor-Independent Prostate Cancer.

Authors:  Yohei Saito; Atsushi Mizokami; Kouji Izumi; Renato Naito; Masuo Goto; Kyoko Nakagawa-Goto
Journal:  Molecules       Date:  2021-05-10       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.